Adverse Events in Families with MYBPC3 Mutations
Author Information
Author(s): Philipp Ehlermann, Dieter Weichenhan, Jörg Zehelein, Henning Steen, Regina Pribe, Raphael Zeller, Stephanie Lehrke, Christian Zugck, Boris T. Ivandic, Hugo A. Katus
Primary Institution: Medizinische Klinik, Abt. Innere Medizin III, Universitätsklinikum Heidelberg, Germany
Hypothesis
The study aims to examine the clinical outcome of patients and their relatives with MYBPC3 mutations.
Conclusion
MYBPC3 mutations can lead to serious cardiac events, including sudden death, even in younger individuals.
Supporting Evidence
- 18 different MYBPC3 mutations were identified in 18 patients.
- 51.1% of patients with cardiomyopathy experienced at least one adverse event.
- Sudden deaths occurred in individuals aged between 13 and 67 years.
Takeaway
Some people in families with a specific gene mutation can have serious heart problems, even when they seem healthy.
Methodology
87 patients with HCM and 71 patients with DCM were screened for MYBPC3 mutations, and relatives were evaluated for adverse events.
Potential Biases
Referral bias may exist as the study primarily included patients undergoing diagnostic procedures.
Limitations
Genotype and phenotype data of deceased family members are often unavailable, which may affect the understanding of adverse events.
Participant Demographics
Patients included 87 with hypertrophic cardiomyopathy (HCM) and 71 with dilated cardiomyopathy (DCM).
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website